CBPO - China Biologic Products Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
114.20
+0.21 (+0.18%)
At close: 4:00PM EDT

114.20 0.00 (0.00%)
After hours: 4:37PM EDT

Stock chart is not supported by your current browser
Previous Close113.99
Open114.08
Bid114.27 x 800
Ask114.33 x 800
Day's Range113.20 - 115.00
52 Week Range60.08 - 115.74
Volume473,296
Avg. Volume142,848
Market Cap4.829B
Beta (3Y Monthly)0.80
PE Ratio (TTM)30.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire

    China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

    BEIJING, Sept. 18, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter, dated September 18, 2019, from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd (collectively, the "Buyer Group"), proposing to acquire all of the outstanding ordinary shares of the Company not already owned by the Buyer Group for US$120 per share in cash in a "going private" transaction (the "Transaction").

  • ACCESSWIRE

    China Biologic Products Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2019 / China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August ...

  • PR Newswire

    China Biologic Reports Financial Results for the Second Quarter of 2019

    --2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million ; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms -- --1H19 Total Sales Up 14.0% ...

  • PR Newswire

    China Biologic Products to Report Second Quarter 2019 Financial Results

    BEIJING , July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • PR Newswire

    China Biologic Reports Financial Results for the First Quarter of 2019

    --1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million ; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING , May 10, 2019 /PRNewswire/ ...

  • PR Newswire

    China Biologic Products to Report First Quarter 2019 Financial Results

    BEIJING , April 30, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • PR Newswire

    China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018

    -- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million ; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total Sales ...

  • PR Newswire

    China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results

    BEIJING , Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • PR Newswire

    China Biologic Reiterates Full Year 2018 Financial Forecast

    BEIJING, Jan. 7, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its previously revised full year 2018 forecast. Full year 2018 non-GAAP adjusted income from operations is expected to increase in the range of 0% to 2% in RMB terms and non-GAAP adjusted net income is expected to decrease by 2% to 4% in RMB terms over full year 2017 financial results. Excluding TianXinFu, full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.

  • Business Wire

    David Gao Issues Statement Following Decision by the Grand Court of the Cayman Islands

    “I am disappointed that my lawsuit was dismissed and will evaluate all options as I continue my efforts to protect my and other minority shareholders’ interests in the company. “It is unfortunate that the legal process is hindered because of a Cayman law technicality with regard to my standing to file such a lawsuit before the court can hear the substance of the case regarding the improper purpose of the Board’s actions. The Board’s hastily arranged private placement to a small group of handpicked investors, including Centurium Capital, Chairman David Li’s private equity fund, improperly transferred voting power away from the minority shareholders.

  • PR Newswire

    China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman

    BEIJING , Dec. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) (" China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • PR Newswire

    China Biologic Reports Financial Results for the Third Quarter of 2018

    3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Di rectors Ap proves $100 ...

  • PR Newswire

    China Biologic Products to Report Third Quarter 2018 Financial Results

    BEIJING , Oct. 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...